JP7321017B2 - 機能性食品 - Google Patents
機能性食品 Download PDFInfo
- Publication number
- JP7321017B2 JP7321017B2 JP2019132196A JP2019132196A JP7321017B2 JP 7321017 B2 JP7321017 B2 JP 7321017B2 JP 2019132196 A JP2019132196 A JP 2019132196A JP 2019132196 A JP2019132196 A JP 2019132196A JP 7321017 B2 JP7321017 B2 JP 7321017B2
- Authority
- JP
- Japan
- Prior art keywords
- imdp
- score
- mci
- functional food
- creatinine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000013376 functional food Nutrition 0.000 title claims description 7
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 34
- 208000010877 cognitive disease Diseases 0.000 claims description 29
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 29
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 26
- 229940109239 creatinine Drugs 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 17
- 206010012289 Dementia Diseases 0.000 claims description 13
- 230000003078 antioxidant effect Effects 0.000 claims description 12
- 108010016626 Dipeptides Proteins 0.000 claims description 10
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 8
- 241000972773 Aulopiformes Species 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- 235000001785 ferulic acid Nutrition 0.000 claims description 8
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 8
- 229940114124 ferulic acid Drugs 0.000 claims description 8
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 8
- 235000019515 salmon Nutrition 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 8
- 230000003907 kidney function Effects 0.000 claims description 7
- 241000287828 Gallus gallus Species 0.000 claims description 5
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 4
- 235000013793 astaxanthin Nutrition 0.000 claims description 4
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 4
- 229940022405 astaxanthin Drugs 0.000 claims description 4
- 239000001168 astaxanthin Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000001149 cognitive effect Effects 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 108010085443 Anserine Proteins 0.000 description 13
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 13
- 241000210053 Potentilla elegans Species 0.000 description 13
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 8
- 229930003268 Vitamin C Natural products 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 235000019154 vitamin C Nutrition 0.000 description 8
- 239000011718 vitamin C Substances 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 230000007850 degeneration Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000032683 aging Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000006933 amyloid-beta aggregation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 235000021194 placebo diet Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- 108010087806 Carnosine Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 229940044199 carnosine Drugs 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- -1 valenine Chemical compound 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CCLQKVKJOGVQLU-QMMMGPOBSA-N L-homocarnosine Chemical compound NCCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 CCLQKVKJOGVQLU-QMMMGPOBSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 108700002498 homocarnosine Proteins 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Steroid Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019132196A JP7321017B2 (ja) | 2019-07-17 | 2019-07-17 | 機能性食品 |
| TW109119147A TWI801737B (zh) | 2019-07-17 | 2020-06-08 | 輕度認知障礙改善用組成物及使用該組成物之輕度認知障礙的改善方法 |
| US16/931,979 US20210015886A1 (en) | 2019-07-17 | 2020-07-17 | Composition for improving mild cognitive impairment and method for improving mild cognitive impairment |
| JP2023064666A JP2023080213A (ja) | 2019-07-17 | 2023-04-12 | 軽度認知障害改善用組成物 |
| JP2023097266A JP2023113933A (ja) | 2019-07-17 | 2023-06-13 | 軽度認知障害改善用組成物 |
| US18/360,773 US20230364180A1 (en) | 2019-07-17 | 2023-07-27 | Composition for improving mild cognitive impairment and method for improving mild cognitive impairment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019132196A JP7321017B2 (ja) | 2019-07-17 | 2019-07-17 | 機能性食品 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023064666A Division JP2023080213A (ja) | 2019-07-17 | 2023-04-12 | 軽度認知障害改善用組成物 |
| JP2023097266A Division JP2023113933A (ja) | 2019-07-17 | 2023-06-13 | 軽度認知障害改善用組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021017402A JP2021017402A (ja) | 2021-02-15 |
| JP2021017402A5 JP2021017402A5 (https=) | 2022-06-07 |
| JP7321017B2 true JP7321017B2 (ja) | 2023-08-04 |
Family
ID=74343267
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019132196A Active JP7321017B2 (ja) | 2019-07-17 | 2019-07-17 | 機能性食品 |
| JP2023064666A Pending JP2023080213A (ja) | 2019-07-17 | 2023-04-12 | 軽度認知障害改善用組成物 |
| JP2023097266A Pending JP2023113933A (ja) | 2019-07-17 | 2023-06-13 | 軽度認知障害改善用組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023064666A Pending JP2023080213A (ja) | 2019-07-17 | 2023-04-12 | 軽度認知障害改善用組成物 |
| JP2023097266A Pending JP2023113933A (ja) | 2019-07-17 | 2023-06-13 | 軽度認知障害改善用組成物 |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US20210015886A1 (https=) |
| JP (3) | JP7321017B2 (https=) |
| TW (1) | TWI801737B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024179725A (ja) * | 2023-06-15 | 2024-12-26 | 日本予防医薬株式会社 | イミダゾールジペプチドおよび黒大豆種皮抽出物を含有する組成物 |
| JP7714085B1 (ja) | 2024-05-10 | 2025-07-28 | 森永乳業株式会社 | 密封容器入り飲食品及び密封容器入り飲食品の製造方法 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003013514A1 (en) | 2001-08-08 | 2003-02-20 | Carn-Aware Llc | Improving neurological functions |
| JP2005336167A (ja) | 2004-04-30 | 2005-12-08 | Japan Research & Development Association For New Functional Foods | 抗酸化性組成物 |
| JP2009046451A (ja) | 2007-08-22 | 2009-03-05 | Tokai Bussan Kk | 抗酸化性ジペプチドの製造方法 |
| JP2013526518A (ja) | 2010-05-13 | 2013-06-24 | ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | Ｍｃｉおよびアルツハイマー病の処置 |
| JP2015193582A (ja) | 2014-03-28 | 2015-11-05 | 国立大学法人 東京大学 | イミダゾールジペプチドを含む剤 |
| JP2018030809A (ja) | 2016-08-24 | 2018-03-01 | 日本ハム株式会社 | イミダゾールジペプチドを含有する、グリア細胞における神経栄養因子等の遺伝子の発現誘導剤 |
| JP2018515145A (ja) | 2015-05-18 | 2018-06-14 | エイエヌティー ラブス インコーポレイテッドＡｎｔ Ｌａｂｓ Ｉｎｃ． | 初期アルツハイマー病又は軽度認知障害の診断方法 |
| JP2018102287A (ja) | 2016-12-27 | 2018-07-05 | 東海物産株式会社 | イミダゾールジペプチド合成活性を有するタンパク質及びイミダゾールジペプチドの製造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0920661A (ja) * | 1995-07-04 | 1997-01-21 | Suntory Ltd | 学習能力向上組成物 |
| JP4023648B2 (ja) * | 1999-01-13 | 2007-12-19 | 日本ハム株式会社 | 皮膚代謝促進物及び機能性食品 |
| ATE328596T1 (de) * | 2001-03-16 | 2006-06-15 | Suntory Ltd | Autonomsystem kontrollagentien und gesundheitsgetränke und -nahrungsmittel |
| JP2007070316A (ja) * | 2005-09-09 | 2007-03-22 | Nippon Meat Packers Inc | 経口用組成物及び栄養補助食品 |
| JP2014142910A (ja) * | 2012-12-28 | 2014-08-07 | Panasonic Corp | 制御装置、発電制御装置、太陽光発電システム、制御方法、及び発電制御方法 |
-
2019
- 2019-07-17 JP JP2019132196A patent/JP7321017B2/ja active Active
-
2020
- 2020-06-08 TW TW109119147A patent/TWI801737B/zh active
- 2020-07-17 US US16/931,979 patent/US20210015886A1/en not_active Abandoned
-
2023
- 2023-04-12 JP JP2023064666A patent/JP2023080213A/ja active Pending
- 2023-06-13 JP JP2023097266A patent/JP2023113933A/ja active Pending
- 2023-07-27 US US18/360,773 patent/US20230364180A1/en not_active Abandoned
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003013514A1 (en) | 2001-08-08 | 2003-02-20 | Carn-Aware Llc | Improving neurological functions |
| JP2005336167A (ja) | 2004-04-30 | 2005-12-08 | Japan Research & Development Association For New Functional Foods | 抗酸化性組成物 |
| JP2009046451A (ja) | 2007-08-22 | 2009-03-05 | Tokai Bussan Kk | 抗酸化性ジペプチドの製造方法 |
| JP2013526518A (ja) | 2010-05-13 | 2013-06-24 | ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | Ｍｃｉおよびアルツハイマー病の処置 |
| JP2015193582A (ja) | 2014-03-28 | 2015-11-05 | 国立大学法人 東京大学 | イミダゾールジペプチドを含む剤 |
| JP2018515145A (ja) | 2015-05-18 | 2018-06-14 | エイエヌティー ラブス インコーポレイテッドＡｎｔ Ｌａｂｓ Ｉｎｃ． | 初期アルツハイマー病又は軽度認知障害の診断方法 |
| JP2018030809A (ja) | 2016-08-24 | 2018-03-01 | 日本ハム株式会社 | イミダゾールジペプチドを含有する、グリア細胞における神経栄養因子等の遺伝子の発現誘導剤 |
| JP2018102287A (ja) | 2016-12-27 | 2018-07-05 | 東海物産株式会社 | イミダゾールジペプチド合成活性を有するタンパク質及びイミダゾールジペプチドの製造方法 |
Non-Patent Citations (2)
| Title |
|---|
| 日本語版MoCA 軽度認知障害スクリーニング （Instruction manual of Japanese version of Montreal Cognitive Assessment），st-medica[online]，2013年03月，https://www.st-medica.com/2013/03/，[検索日:2023.2.24] |
| 舛岡 伸高，鶏肉イミダゾールジプチド摂取によるアルツハイマー病予防の可能性，日本農芸化学会２０１８年度大会講演要旨集（オンライン） ，日本，公益社団法人日本農芸化学会 JSBBA |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230364180A1 (en) | 2023-11-16 |
| JP2023080213A (ja) | 2023-06-08 |
| TW202116345A (zh) | 2021-05-01 |
| US20210015886A1 (en) | 2021-01-21 |
| JP2021017402A (ja) | 2021-02-15 |
| TWI801737B (zh) | 2023-05-11 |
| JP2023113933A (ja) | 2023-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aliasgharpour et al. | Trace elements in human nutrition: A review | |
| US20120141611A1 (en) | Methods and compositions using ergothioneine to treat a variety of health related factors | |
| JP2023113933A (ja) | 軽度認知障害改善用組成物 | |
| KR20260048483A (ko) | 인지 기능 속도 개선용 조성물 | |
| US20250090546A1 (en) | Chlorophyll composition | |
| Singh | Antioxidants as a preventive therapeutic option for age related neurodegenerative diseases | |
| KR20140136915A (ko) | 세포손상 효과에 대한 보호를 제공하는 조성물 | |
| JP5089025B2 (ja) | 抗酸化組成物 | |
| EP1575593A2 (de) | VERWENDUNG VON TETRAHYDROBIOPTERINDERIVATEN ZUR BEHANDLUNG UND ERN HRUNG VON PATIENTEN MIT AMINOS URESTOFFWECHSELST&Ouml ;RUNGEN | |
| Singh et al. | 19 Vitamins and Minerals: Roles and Plant Sources | |
| JP2004231902A (ja) | 抗酸化性組成物 | |
| JPWO2016052509A1 (ja) | 腎不全進行抑制剤、腎不全予防剤及びインドキシル硫酸産生阻害剤 | |
| US20050250703A1 (en) | Antioxidant constituents | |
| JP3713553B2 (ja) | アルギニンとｒｎａを含有する脳脊髄系神経栄養剤 | |
| KR102323577B1 (ko) | 부채마와 백년초의 혼합추출물을 포함하는 우울증 예방 또는 치료용 조성물 | |
| Stephens et al. | Aluminum and Alzheimer’s disease | |
| Todorov et al. | Overview of cognitive dysfunction syndrome in ageing dogs | |
| JP5749469B2 (ja) | 血圧降下剤 | |
| TWI745609B (zh) | 具抗氧化活性之組合物 | |
| JP4974475B2 (ja) | アカシア属樹皮由来物を含有する掻痒の予防及び／又は治療用組成物 | |
| JP2008067637A (ja) | 健康補助食品 | |
| US20210322353A1 (en) | Nutritional composition for the treatment of metabolic diseases | |
| Fox | Heart Health With Natural Medicine | |
| JP2004175695A (ja) | 記憶障害改善作用を有する組成物 | |
| EA048916B1 (ru) | Применение хлорофиллина для лечения заболеваний почек, терапевтические композиции хлорофиллина и способ лечения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220530 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230302 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230412 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230608 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230613 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230621 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230724 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230725 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7321017 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |